Results 101 to 110 of about 1,984,318 (387)

Application of secondary of polymers and surface active agents to increase heavy oil recovery [PDF]

open access: yesActa Montanistica Slovaca, 2006
Basin on a comparison of laboratory results with results obtained by screening modelling, one of the most promising methods was selected – the method of oil displacement by means of the polymer injection.Water intended for the injection is thickened with
Karel Luner, Karel Bříza, Petr Bujok
doaj  

Quantifying surfactant interaction effects on soil moisture and turf quality [PDF]

open access: yes, 2009
Soil water repellency occurs widely in horticultural and agricultural soils when very dry. The gradual accumulation and breakdown of surface organic matter over time produces wax-like organic acids, which coat soil particles preventing uniform entry of ...
Bauer, B., Duff, A.A., Poulter, R.E.
core   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Sustained antibacterial coating with graphene oxide ultrathin film combined with cationic surface-active agents in a wet environment. [PDF]

open access: yesSci Rep, 2022
Miyaji H   +11 more
europepmc   +1 more source

THE INFLUENCE OF INTRAVENOUSLY ADMINISTERED SURFACE-ACTIVE AGENTS ON THE DEVELOPMENT OF EXPERIMENTAL ATHEROSCLEROSIS IN RABBITS

open access: yesJournal of Experimental Medicine, 1951
A study was made of the relationship of blood lipids to the development of experimental atherosclerosis. Rabbits fed a diet containing cholesterol were found to develop hyperlipemia characterized by a great increase in blood cholesterol and a much lesser
A. Kellner, J. Correll, A. T. Ladd
semanticscholar   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Fast track on the surface active agents involved in nanoemulsion for drug delivery

open access: yesAl-Mustansiriyah Journal of Pharmaceutical Sciences
Nanoemulsions (NEs) are colloidal dispersion systems made of two immiscible liquids combined with co-surfactants and surfactants (emulsifying agents), to form a thermodynamically stable. Numerous synthetic and natural compounds with the aim of enhancing
Sara Abdullah Challoob   +2 more
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy